Pharmacyclics Hits Highest Price in Decade on Drug Status

Pharmacyclics Inc., a drugmaker developing an experimental therapy for blood cancers, rose to its highest level in more than a decade after gaining “breakthrough” status from U.S. regulators.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.